U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505095) titled 'Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice' on March 26.
Brief Summary: This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.
Study Start Date: April 30
Study Type: OBSERVATIONAL
Condition:
Alzheimer Disease (AD)
Alzheimer Deme...